Publications by authors named "Hiasa Y"

Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev).

Methods: A total of 462 patients with Atezo/Bev-treated HCC diagnosed with radiological PD during follow-up were enrolled. PD was classified into three categories: progression or emergence of intrahepatic lesions (PD-IH), macroscopic vascular invasion (PD-MVI), and extrahepatic spread lesions (PD-EHS).

View Article and Find Full Text PDF

Aim: This study aims to investigate the clinical utility of the derived neutrophil-to-lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable hepatocellular carcinoma (HCC) undergoing combination therapy with atezolizumab and bevacizumab (Atez/Bev).

Methods: A retrospective analysis was conducted on 310 patients. The dNLR, NLR, and GNRI were calculated, and their impact on progression-free survival (PFS) and overall survival (OS) was assessed.

View Article and Find Full Text PDF

Unlabelled: The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments.

View Article and Find Full Text PDF

Allergic diseases and ulcerative colitis (UC) share pathophysiological similarities. This study aimed to investigate the unclear association between allergic diseases and mucosal healing (MH), an important factor in the prognosis of UC. We studied 289 Japanese patients with UC.

View Article and Find Full Text PDF

Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment.

Methods: Among 449 patients included in this retrospective multicenter study, we compared the prognostic performance of 13 risk models for the 12-month and 18-month survival status using area under the curve (AUC), net reclassification improvement (NRI), and relative integrated discrimination improvement (IDI) analysis. We also constructed a calibration plot to assess the fitness of each model.

View Article and Find Full Text PDF

In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73).

View Article and Find Full Text PDF

While the effectiveness of metabolic/bariatric surgery has been confirmed, understanding the factors associated with weight loss is paramount for providing guidance in postoperative treatment strategies. Here, we aimed to examine the factors associated with long-term maintenance of weight loss after laparoscopic sleeve gastrectomy (LSG). This prospective observational cohort included patients who underwent LSG at a single academic health center between January 2017 and June 2022.

View Article and Find Full Text PDF

Background: Constipation is a very common medical issue among the general population worldwide. However, the association between exercise habits and constipation is still not fully understood. Additionally, no evidence regarding the association between exercise partners and constipation exists.

View Article and Find Full Text PDF

Background And Aims: This study prospectively compared the diagnostic accuracies of the improved Attenuation Measurement (iATT) algorithm and the Controlled Attenuation Parameter (CAP) and assessed the interchangeability of iATT with magnetic resonance imaging-derived proton density fat fraction (MRI-derived PDFF).

Methods: Patients with chronic liver disease were prospectively enrolled and underwent iATT, CAP and MRI-derived PDFF measurements for hepatic steatosis evaluation. According to MRI-derived PDFF values, steatosis grades were categorised as steatosis (S)0 (< 5.

View Article and Find Full Text PDF

Background: Direct measurement of portal venous pressure (PVP) is invasive, so the hepatic venous pressure gradient (HVPG) is commonly measured to evaluate portal hypertension (PH). HVPG is the gold standard for estimating PVP but few reports have covered standardized measurement techniques.

Methods: This study validated standardized techniques for PVP measurement.

View Article and Find Full Text PDF

Background: The clinical course of esophagogastric varices (EGV) after sustained virological response (SVR) with direct-acting antiviral (DAA) therapy has not been clearly elucidated. The predictors for the worsening/improvement of EGV after SVR with DAA therapy were investigated.

Methods: Of the cirrhosis patients who achieved SVR with DAA therapy, 328 patients who underwent endoscopic examinations both before and after DAA therapy were enrolled.

View Article and Find Full Text PDF

RNA-dependent protein kinase (PKR) may have a positive regulatory role in controlling tumor growth and progression in hepatocellular carcinoma (HCC). However, the downstream substrates and the molecular mechanism of PKR in the growth and progression of HCC have not been clarified. In this study, mass spectrometry analysis was performed with immunoprecipitated samples, and 4.

View Article and Find Full Text PDF

Aim: Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical practice. This study aimed to elucidate clinical prognostic factors for progression-free survival (PFS) in Dur/Tre treatment cases.

Methods: Enrolled were 183 uHCC patients treated with Dur/Tre from 2023 to May 2024 (median age, 74 years; male patients, 152; Child-Pugh class A:B, 150:33; Barcelona Clinic Liver Cancer stage B:C, 59:124; initial line use, 64).

View Article and Find Full Text PDF

Baveno VII criteria (B7C) and Baveno VI criteria (B6C) have been widely used to estimate the risk of hepatic decompensation. However, the impact of age on these criteria warrants further investigation. The international, multicenter cohort study included 1138 patients with compensated cirrhosis (median follow-up of 40.

View Article and Find Full Text PDF

An Impella device (Abiomed, Inc., Danvers, Massachusetts, United States) is a useful percutaneous left ventricular assist device for patients with cardiogenic shock. However, there are cases in which patients are unable to escape cardiogenic shock and become Impella-dependent.

View Article and Find Full Text PDF

Aim: The incidence of and factors involved in gastroesophageal varix-related events in hepatitis C virus-related cirrhosis patients, including decompensated cirrhosis, after direct-acting antiviral therapy are unclear.

Methods: We conducted a multicenter study using prospective data from 478 hepatitis C virus-related cirrhosis patients treated with direct-acting antiviral therapy from February 2019 to December 2021 at 33 Japanese hospitals. Gastroesophageal varices were classified as F1 (small-caliber), F2 (moderately enlarged), or F3 (markedly enlarged) according to the Japanese criteria.

View Article and Find Full Text PDF

Introduction: The most frequently used first-line treatment in patients with advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab. Upon progression after this treatment, the standard of care in many countries is sorafenib, due to the lack of reimbursement for other drugs. Several randomized trials are currently underway to clarify the best second-line therapy in patients with HCC.

View Article and Find Full Text PDF
Article Synopsis
  • Aromatase inhibitors (AIs) are commonly used for treating hormone receptor-positive postmenopausal breast cancer, but there's concern regarding their potential cardiovascular risks due to estrogen suppression.
  • A study involving 357 breast cancer patients found that nearly 45% had coronary artery calcification (CAC), but the duration of AI treatment did not significantly differ between those with and without CAC.
  • Key risk factors for higher CAC scores included advanced age, lower hemoglobin levels, and higher rates of conditions like hypertension and diabetes, indicating that treatment duration alone isn’t a major concern for CAC severity.
View Article and Find Full Text PDF
Article Synopsis
  • * A retrospective analysis of 885 HCC patients showed no significant differences in overall survival, time to progression, or disease control rates between viral and nonviral patients treated with the combination therapy.
  • * Common prognostic factors were identified across both groups, but there might be some stronger associations between immunological factors and outcomes specifically in viral patients, while treatment-related toxicities and second-line treatments showed nearly identical results for both etiology subgroups.
View Article and Find Full Text PDF
Article Synopsis
  • - This study investigates what factors predict conversion therapy success in patients with unresectable hepatocellular carcinoma (uHCC) and compares the survival outcomes of those who underwent conversion therapy to those with partial or complete responses after treatment with atezolizumab and bevacizumab.
  • - Out of 946 uHCC patients studied, only 43 (4.5%) received conversion therapy, with a higher overall response rate in this group (65.1%) compared to those who did not undergo conversion therapy (23.7%), indicating a statistically significant difference.
  • - Factors such as earlier BCLC stage, lack of macrovascular invasion or extrahepatic spread, and low neutrophil to lymphocyte ratio were found
View Article and Find Full Text PDF

Background: Interleukin (IL)-23 is involved in the pathogenesis of ulcerative colitis (UC). A genome-wide significant association between IL23R p.G149R (rs76418789) and UC was previously identified in Japan and Korea.

View Article and Find Full Text PDF

Context: Estimated remnant cholesterol (Rem-C) level, a risk factor for cardiovascular disease (CVD), is associated with metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosed via ultrasonography. However, the relationship between accurate serum Rem-C level measurements and histological findings of MASLD remains unclear.

Objective: We aimed to elucidate the relationship between accurately measured serum Rem-C levels and histological findings of MASLD.

View Article and Find Full Text PDF
Article Synopsis
  • Nocturia, or frequent nighttime urination, is a common symptom in patients with lower urinary tract syndrome (LUTS), and its link to ulcerative colitis (UC) has not been widely studied.
  • A study was conducted with 287 Japanese UC patients, who were categorized based on their nighttime urination frequency and evaluated for mucosal healing (MH) and clinical remission (CR) using survey data.
  • Results indicated that higher frequencies of nighttime urination are associated with lower rates of mucosal healing, particularly in younger patients and those in clinical remission, suggesting that nocturia could be a potential indicator of disease status in UC patients.
View Article and Find Full Text PDF